Transcend Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Transcend Capital Advisors's VRTX Position: Q2 2026 in Review
Transcend Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2026, buying an estimated $207K and bringing the position to 2,971 shares worth $1.48M. The position accounts for 0.1% of the portfolio, ranked #193.
Transcend Capital Advisors first reported a position in VRTX in Q4 2022 and has held it in 10 quarters since. The position peaked at $1.58M in Q1 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Transcend Capital Advisors held 2,971 shares of Vertex Pharmaceuticals worth $1.48M as of Q2 2026.
- Transcend Capital Advisors bought 468 Vertex Pharmaceuticals shares in Q2 2026, an estimated $207K.
- Vertex Pharmaceuticals made up 0.1% of Transcend Capital Advisors's portfolio in Q2 2026, its #193 holding.
- Transcend Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
- Transcend Capital Advisors's Vertex Pharmaceuticals position peaked at $1.58M in Q1 2025.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.